Moffitt begins drug trial
Introgen Therapeutics Inc. and the H. Lee Moffitt Cancer Center & Research Institute said they would begin a Phase 2 study of an investigational immunotherapy product for patients with metastatic small-cell lung cancer.
This entry was posted on Thursday, September 6th, 2007 at 12:26 pm and is filed under Research, Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.